The anti-obesity drug due for launch next year by Sanofi-Aventis eventually could generate sales of more than $3 billion a year, the company's chief said. Jean-Francois Dehecq stressed that Acomplia, which also helps people quit smoking, would be marketed as a serious treatment for life-threatening conditions, and not as a lifestyle drug.

Full Story:

Related Summaries